Preclinical studies evaluating the receptor activated nuclear factor kappa-B ligand (RANKL) on breast cell proliferation, have shown that RANKL driven progesterone signaling can play a critical role in breast cancer tumorigenesis among BRCA1 mutation carriers [8–14]. Here, BRCA1 is linked to breast cancer.